SMARCB1 and neoplasm: Some studies have recently suggested the partial loss of SMARCB1/INI1 expression at immunohistochemistry as a poor prognostic marker of outcome, being associated with higher recurrence rates and shorter survival in patients with other tumor types, including colorectal, pancreatic, uterine and sinonasal carcinomas (12–16).